源自美国疾病控制与预防中心。最新消息：利福平和吡嗪酰胺用于潜伏性结核感染相关的致命性和严重性肝损伤，以及美国胸科学会/疾病控制与预防中心建议的修订——美国，2001年 - Suppr | 超能文献

From the Centers for Disease Control and Prevention. Update: Fatal and severe liver injuries associated with Rifampin and Pyrazinamide for latent tuberculosis infection, and revisions in American Thoracic Society/CDC recommendations--United States, 2001.

出版信息

JAMA. 2001 Sep 26;286(12):1445-6.

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

From the Centers for Disease Control and Prevention. Update: Fatal and severe liver injuries associated with Rifampin and Pyrazinamide for latent tuberculosis infection, and revisions in American Thoracic Society/CDC recommendations--United States, 2001.源自美国疾病控制与预防中心。最新消息：利福平和吡嗪酰胺用于潜伏性结核感染相关的致命性和严重性肝损伤，以及美国胸科学会/疾病控制与预防中心建议的修订——美国，2001年

JAMA. 2001 Sep 26;286(12):1445-6.

2

Update: Fatal and severe liver injuries associated with rifampin and pyrazinamide for latent tuberculosis infection, and revisions in American Thoracic Society/CDC recommendations--United States, 2001.最新消息：利福平与吡嗪酰胺用于潜伏性结核感染导致的致命性和严重性肝损伤，以及美国胸科学会/疾病控制与预防中心建议的修订——美国，2001年

MMWR Morb Mortal Wkly Rep. 2001 Aug 31;50(34):733-5.

3

Update: Fatal and severe liver injuries associated with rifampin and pyrazinamide treatment for latent tuberculosis infection.最新消息：利福平与吡嗪酰胺治疗潜伏性结核感染相关的致命性和严重性肝损伤。

MMWR Morb Mortal Wkly Rep. 2002 Nov 8;51(44):998-9.

4

From the Centers for Disease Control and Prevention. Update: fatal and severe liver injuries associated with rifampin and pyrazinamide treatment for latent tuberculosis infection.源自疾病控制与预防中心。更新：利福平与吡嗪酰胺治疗潜伏性结核感染相关的致命性和严重肝损伤。

JAMA. 2002 Dec 18;288(23):2967. doi: 10.1001/jama.288.23.2967-jwr1218-6-1.

5

From the Centers for Disease Control and Prevention. Fatal and severe hepatitis associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection--New York and Georgia, 2000.

JAMA. 2001;285(20):2572-3.

6

Update: adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection--United States, 2003.更新：不良事件数据及美国胸科学会/疾病控制与预防中心关于不使用利福平和吡嗪酰胺治疗潜伏性结核感染的修订建议——美国，2003年

MMWR Morb Mortal Wkly Rep. 2003 Aug 8;52(31):735-9.

7

National survey to measure rates of liver injury, hospitalization, and death associated with rifampin and pyrazinamide for latent tuberculosis infection.

Clin Infect Dis. 2005 Oct 15;41(8):1125-33. doi: 10.1086/444463. Epub 2005 Sep 9.

8

Rifampin and pyrazinamide for treatment of latent tuberculosis infection.利福平和吡嗪酰胺用于治疗潜伏性结核感染。

Clin Infect Dis. 2006 Mar 15;42(6):892; author reply 892-3. doi: 10.1086/500458.

9

Severe hepatotoxicity associated with rifampin-pyrazinamide preventative therapy requiring transplantation in an individual at low risk for hepatotoxicity.与利福平-吡嗪酰胺预防性治疗相关的严重肝毒性，该治疗导致一名肝毒性低风险个体需要进行移植。

Clin Infect Dis. 2003 Jun 15;36(12):e158-61. doi: 10.1086/375072. Epub 2003 Jun 6.

10

Severe or fatal liver injury in 50 patients in the United States taking rifampin and pyrazinamide for latent tuberculosis infection.

Clin Infect Dis. 2006 Feb 1;42(3):346-55. doi: 10.1086/499244. Epub 2005 Dec 28.

引用本文的文献

1

The Characteristics, Prevalence, and Risk Factors of Drug-Induced Liver Injury Among Brucellosis Inpatients in Xinjiang, China.中国新疆布鲁氏菌病住院患者药物性肝损伤的特征、患病率及危险因素

Front Pharmacol. 2021 May 10;12:657805. doi: 10.3389/fphar.2021.657805. eCollection 2021.

2

Updates on the risk factors for latent tuberculosis reactivation and their managements.潜伏性结核再激活的危险因素及其管理的最新进展。

Emerg Microbes Infect. 2016 Feb 3;5(2):e10. doi: 10.1038/emi.2016.10.

3

Adverse events associated with treatment of latent tuberculosis in the general population.普通人群潜伏性结核治疗的不良反应。

CMAJ. 2011 Feb 22;183(3):E173-9. doi: 10.1503/cmaj.091824. Epub 2011 Jan 10.